JP6727237B2 - 血液がん及び固形腫瘍の治療のための併用療法 - Google Patents

血液がん及び固形腫瘍の治療のための併用療法 Download PDF

Info

Publication number
JP6727237B2
JP6727237B2 JP2017568243A JP2017568243A JP6727237B2 JP 6727237 B2 JP6727237 B2 JP 6727237B2 JP 2017568243 A JP2017568243 A JP 2017568243A JP 2017568243 A JP2017568243 A JP 2017568243A JP 6727237 B2 JP6727237 B2 JP 6727237B2
Authority
JP
Japan
Prior art keywords
compound
administered
day
days
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017568243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018524347A5 (enExample
JP2018524347A (ja
Inventor
ガンディー アニタ
ガンディー アニタ
チウ フシリング
チウ フシリング
ポウルデフナド マイケル
ポウルデフナド マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2018524347A publication Critical patent/JP2018524347A/ja
Publication of JP2018524347A5 publication Critical patent/JP2018524347A5/ja
Application granted granted Critical
Publication of JP6727237B2 publication Critical patent/JP6727237B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017568243A 2015-07-02 2016-07-01 血液がん及び固形腫瘍の治療のための併用療法 Expired - Fee Related JP6727237B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562188404P 2015-07-02 2015-07-02
US62/188,404 2015-07-02
US201562245916P 2015-10-23 2015-10-23
US62/245,916 2015-10-23
US201662308055P 2016-03-14 2016-03-14
US62/308,055 2016-03-14
US201662340972P 2016-05-24 2016-05-24
US62/340,972 2016-05-24
PCT/US2016/040718 WO2017004532A1 (en) 2015-07-02 2016-07-01 Combination therapy for treatment of hematological cancers and solid tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020112519A Division JP2020172502A (ja) 2015-07-02 2020-06-30 血液がん及び固形腫瘍の治療のための併用療法

Publications (3)

Publication Number Publication Date
JP2018524347A JP2018524347A (ja) 2018-08-30
JP2018524347A5 JP2018524347A5 (enExample) 2019-08-15
JP6727237B2 true JP6727237B2 (ja) 2020-07-22

Family

ID=56418624

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568243A Expired - Fee Related JP6727237B2 (ja) 2015-07-02 2016-07-01 血液がん及び固形腫瘍の治療のための併用療法
JP2020112519A Pending JP2020172502A (ja) 2015-07-02 2020-06-30 血液がん及び固形腫瘍の治療のための併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020112519A Pending JP2020172502A (ja) 2015-07-02 2020-06-30 血液がん及び固形腫瘍の治療のための併用療法

Country Status (10)

Country Link
US (1) US10973822B2 (enExample)
EP (1) EP3316888A1 (enExample)
JP (2) JP6727237B2 (enExample)
KR (1) KR20180023968A (enExample)
AU (1) AU2016288246A1 (enExample)
BR (1) BR112017028530A2 (enExample)
CA (1) CA2991164A1 (enExample)
EA (1) EA201890199A1 (enExample)
MX (1) MX2018000216A (enExample)
WO (1) WO2017004532A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309273A (en) 2015-10-21 2024-02-01 Teclison Ltd Preparations and methods for curing cancer with immune support
JP2018535992A (ja) 2015-12-02 2018-12-06 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを使用するサイクリング療法
WO2018078123A1 (en) 2016-10-28 2018-05-03 Morphosys Ag Combination of anti cd19 antibody with a bcl-2 inhibitor and uses thereof
JP7301002B2 (ja) 2017-05-30 2023-06-30 ブリストル－マイヤーズ スクイブ カンパニー 抗ｌａｇ－３抗体または抗ｌａｇ－３抗体および抗ｐｄ－１もしくは抗ｐｄ－ｌ１抗体を含む組成物
CN119280245A (zh) 2017-06-12 2025-01-10 法国施维雅药厂 使用组合疗法治疗脑肿瘤的方法
KR20200027502A (ko) 2017-06-12 2020-03-12 아지오스 파마슈티컬스 아이엔씨. 병용 요법을 사용한 뇌 종양 치료 방법
EA202090565A1 (ru) * 2017-10-13 2020-10-13 Мерк Шарп энд Доум Корп. Композиции и способы лечения диффузной в-крупноклеточной лимфомы
WO2019094931A1 (en) * 2017-11-10 2019-05-16 Actinium Pharmaceuticals, Inc. Combination therapy for treatment of a hematological disease
WO2020025532A1 (en) * 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
EP3974455A4 (en) * 2019-05-21 2023-06-14 Kuraray Noritake Dental Inc. RESIN COMPOSITION FOR OPTICAL THREE-DIMENSIONAL MODELING
WO2021041669A1 (en) * 2019-08-30 2021-03-04 Dana-Farber Cancer Institute, Inc. Immune signatures predictive of response to pd-1 blockade in richter's transformation
US11839619B2 (en) * 2019-09-16 2023-12-12 The Regents Of The University Of California Methods for treatment of pediatric systemic mastocytosis
WO2021092190A1 (en) * 2019-11-05 2021-05-14 Health Research, Inc. Combination therapy for cancer
EP4073517A1 (en) * 2019-12-11 2022-10-19 Erasmus University Rotterdam Medical Center Method for monitoring of deep remissions in multiple myeloma and other plasma cell dyscrasias
US20220117929A1 (en) * 2020-10-21 2022-04-21 Buddhist Tzu Chi Medical Foundation Method for preventing or treating high-grade serous carcinoma
US12523658B2 (en) * 2021-08-27 2026-01-13 The Board Of Regents Of The University Of Texas System Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications
WO2023077090A1 (en) * 2021-10-29 2023-05-04 Bristol-Myers Squibb Company Lag-3 antagonist therapy for hematological cancer
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CN115137731B (zh) * 2022-05-19 2023-11-21 上海交通大学医学院附属新华医院 Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
HUE035389T2 (en) 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
AU2008305581C1 (en) 2007-09-26 2014-12-11 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
SI2683384T1 (sl) * 2011-03-11 2016-05-31 Celgene Corporation Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
RU2611007C2 (ru) 2011-03-11 2017-02-17 Селджин Корпорейшн Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
WO2014039421A1 (en) 2012-09-04 2014-03-13 Celgene Corporation Isotopologues of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2-6-dione and methods of preparation thereof
CN104797256A (zh) * 2012-09-10 2015-07-22 细胞基因公司 用于治疗局部晚期乳腺癌的方法
AU2014205043B2 (en) 2013-01-14 2018-10-04 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
HRP20171535T1 (hr) 2013-05-01 2017-11-17 Celgene Corporation Sinteza 3-(5-amino-2-metil-4-oksokinazolin-3(4h)-il)piperidin-2,6-diona
WO2014179661A1 (en) * 2013-05-03 2014-11-06 Celgene Corporation Methods for treating cancer using combination therapy
EA201690912A1 (ru) * 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
WO2015108889A1 (en) 2014-01-15 2015-07-23 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione
US20170128448A1 (en) 2014-07-11 2017-05-11 Celgene Corporation Combination therapy for cancer
US10064863B2 (en) 2015-08-27 2018-09-04 Celgene Corporation Formulations of 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione
JP2018535992A (ja) 2015-12-02 2018-12-06 セルジーン コーポレイション ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを使用するサイクリング療法

Also Published As

Publication number Publication date
KR20180023968A (ko) 2018-03-07
JP2018524347A (ja) 2018-08-30
EA201890199A1 (ru) 2018-06-29
US20180193342A1 (en) 2018-07-12
US10973822B2 (en) 2021-04-13
CA2991164A1 (en) 2017-01-05
JP2020172502A (ja) 2020-10-22
EP3316888A1 (en) 2018-05-09
WO2017004532A1 (en) 2017-01-05
AU2016288246A1 (en) 2018-02-01
BR112017028530A2 (pt) 2018-08-28
MX2018000216A (es) 2018-05-22

Similar Documents

Publication Publication Date Title
US10973822B2 (en) Combination therapy for treatment of hematological cancers and solid tumors
TWI542349B (zh) 利用３－（５－胺基－２－甲基－４－氧基－４ｈ－喹唑啉－３－基）－六氫吡啶－２，６－二酮治療癌症之方法
US20230310354A1 (en) Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
IL262808B2 (en) Combination treatments of hdac inhibitors and pd-l1 inhibitors
IL262814B2 (en) Combination therapies of hdac inhibitors and pd-1 inhibitors
WO2012050374A2 (en) Immunotherapy for solid tumors
MX2015003114A (es) Metodos para el tratamiento de cancer de mama localmente avanzado.
RS64029B1 (sr) Kompozicije i postupci za upotrebu 2-(4-hlorfenil)-n-((2-(2,6-dioksopiperidin-3-il)-1-oksoizoindolin-5-il)metil)-2,2-difluoracetamida
RS51567B (sr) Upotreba 3-(4-amino-1-okso-1,3-dihidro-izoindol-2-il)-piperidin-2,6-diona za lečenje limfoma mantle ćelija
WO2017058754A1 (en) Combination therapy for treatment of hematological cancers and solid tumors
US7893045B2 (en) Methods for treating lymphomas in certain patient populations and screening patients for said therapy
KR20220154175A (ko) 급성 골수성 백혈병에 대한 조합 요법
US12090147B2 (en) Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
KR20180088401A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
US20220110924A1 (en) Methods and compositions for genetic modulation of tumor microenvironments
US20200383961A1 (en) Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors
US20240041865A1 (en) Combination therapies of wdr-5 inhibitors and pd-1 inhibitors
HK40068523A (en) Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
JP2023178473A (ja) 小児患者のがんの治療方法
BR122024004326A2 (pt) Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto
BR122024004327A2 (pt) Combinação, composição farmacêutica, kit, composto, uso de um inibidor da histona desacetilase (inibidor de hdac) e uso de um composto
HK1261967B (en) Cyp26-resistant rar-alpha selective agonists in the treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190627

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190627

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200602

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200630

R150 Certificate of patent or registration of utility model

Ref document number: 6727237

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees